Study Reveals Mechanisms Behind Common Mutation and Prostate Cancer

Translate to Spanish or other 102 languages!

 A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance. Image for illustration purposes
 A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance. Image for illustration purposes
- Advertisement -

By Michigan Medicine – University of Michigan

Newswise – A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

FOXA1, a key transcription factor that facilitates androgen receptor binding to DNA, is mutated in 10–40% of hormone-dependent prostate cancers. While common, the exact ways these mutations alter cancer cells have remained elusive—until now.

- Advertisement -

Rogel researchers, including Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Endowed Professor of Pathology and Urology, and Abhijit Parolia, Ph.D., Rogel Fellow and Assistant Professor of Pathology, used mouse models to understand the mechanisms underlying two major classes of FOXA1 mutations.

In addition to establishing FOXA1 as a true oncogenic driver in prostate cancer, their findings reveal the distinct ways that each class of FOXA1 mutations operate.

Firstly, Class 1 mutations, commonly observed in primary prostate cancer, work with loss of the gene TP53 to promote the formation of aggressive tumors. Like human prostate cancer, tumors in the mouse models retain hormone sensitivity and shrink in response to androgen deprivation therapy.

Alternatively, Class 2 mutations, typically found in metastatic prostate cancer, do not independently initiate tumor growth. Instead, they reprogram the cellular lineage identity, driving resistance to hormonal therapies.

- Advertisement -

“This is the first in vivo demonstration of FOXA1 as an initiator of prostate cancer,” said Chinnaiyan. “Prior studies relied on cell lines, but our mouse models provide definitive evidence of its causal role in tumor development.”

These insights build on earlier work that categorized three major FOXA1 mutation types. “This study goes further,” Chinnaiyan added, “by revealing how distinct alterations within the same gene can initiate disease in early stages or confer resistance in late-stage, therapy-refractory tumors.”

Hormone therapy is central to prostate cancer treatment. Though initially effective, most patients develop resistance to androgen deprivation therapy, leading to incurable disease.

“Modeling primary prostate cancer’s response to androgen withdrawal in mouse models has been challenging” said Parolia. “We demonstrated that prostate tumors driven by Class 1 mutations require continuous androgen supply for growth and survival, establishing the FOXA1/p53 mouse model as a valuable preclinical system.”

In metastatic disease, Class 2 mutants acquire the ability to access latent DNA sites. “Activation of these sites turn on genes that drive adaptation to androgen blockade, enabling cancer’s escape from therapy,” Parolia explained.

The team’s findings reveal two faces of the FOXA1 oncogene and deepen understanding of prostate cancer evolution, while opening potential avenues for FOXA1 mutation-specific therapeutic strategies.

Additional authors: Sanjana Eyunni, Rahul Mannan, Yuping Zhang, Eleanor Young, Qiuyang Zhang, Jie Luo, Matthew Pang, Somnath Mahapatra, Jean Ching-Yi Tien, James M. George , Mustapha Jaber, Hamzah Hakkani , Sandra E. Carson, Abigail J. Todd, Noshad Hosseini, Mahnoor Gondal, Ryan J. Rebernick, Xuhong Cao, Fengyun Su, Rui Wang, Rohit Mehra, Jing Li, Marcin Cieslik

Funding/disclosures: National Cancer Institute (NCI) Specialized Programs of Research Excellence Grant P50-CA186786 (Rogel Cancer Center investigators, including AMC) National Cancer Institute Outstanding Investigator Award R35-CA231996 (AMC) Michigan Prostate SPORE Career Enhancement Program award (AP) NIH K00 Fellowship K00-CA245825 (AP) Rogel Fellowship (AP) Prostate Cancer Foundation Young Investigator Award (AP) V Scholar Award V2024-020 (AP) AMC is a Howard Hughes Medical Institute Investigator, A. Alfred Taubman Scholar, and American Cancer Society Professor.

Conflict(s) of interest: A.M.C. is a co-founder and serves on the scientific advisory board of Lynx Dx, Flamingo Therapeutics, NuLynx Therapeutics, Medsyn Pharma, and Esanik Therapeutics. A.M.C. serves as an advisor to Tempus, Aurigene Oncology, and Ascentage. The remaining authors declare no conflicts of interests.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Mayo Clinic Study Sheds New Light on Memory Loss

A new framework, published in Brain, could reshape researchers' understanding of how the brain creates memories and experiences, and how disruptions in this process may indicate Alzheimer’s disease and other forms of dementia.

United States and Mexico Lose Measles Elimination Status Amid Continued Outbreaks

The United States, Mexico and Bolivia have lost their measles elimination status after the highly contagious virus circulated continuously for more than 12 months, the Pan American Health Organization (PAHO) announced November 17, 2026.

Eating and sleeping later associated with increased health risks

Staying up late and eating later in the evening could increase the risk of metabolic syndrome, a term that refers to conditions that increase the risk of type 2 diabetes, cardiovascular disease, and high cholesterol.

Health Officials Release Joint Statement Regarding Loss of U.S. Measles Elimination Status

CDC and its partners are committed to stopping measles outbreaks, protecting Americans, and regaining measles elimination status.
- Advertisement -